DDInter1197 DDInter1960
Diabetic gastroparesis is a condition that causes frequent nausea and vomiting, which has a negative impact on quality of life and poses a significant burden on the healthcare system. Metoclopramide is a dopamine antagonist used to treat nausea and vomiting that may be associated with diabetic gastroparesis in addition to gastroesophageal reflux disease (GERD). It can also be used to prevent nausea or vomiting associated with chemotherapy or certain surgical or diagnostic procedures. One unique property of this drug is that it does not increase gastric acid secretion. It is available in the oral tablet form or in solution, and can also be administered through the intravenous route. Metoclopramide was initially approved by the FDA in 1980.
Ziconotide (also known as SNX-111) is a neurotoxic peptide derived from the cone snail _Conus magus_ comprising 25 amino acids with three disulphide bonds.[A202835, L13389] Other such peptides, collectively termed conotoxins, exist, and some have shown efficacy in binding specific subsets of calcium channels; ziconotide is used in part because it can be synthesized without loss of proper bond formation or structural elements.[A202829, A202832] Ziconotide is used to manage severe chronic pain refractory to other methods, through its ability to inhibit N-type calcium channels involved in nociceptive signalling.[A202829, A202835, A202838, A202841, A202850, A202859, L13389] Ziconotide was granted FDA approval on December 28, 2004 for marketing by TerSera therapeutics LLC. under the name Prialt. To date, ziconotide is the only calcium channel blocking peptide approved for use by the FDA.
Metoclopramide {u} (Compound) resembles {v} (Compound) Cinchocaine
Metoclopramide {u} (Compound) resembles {v} (Compound) Procaine
Metoclopramide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Procainamide
Metoclopramide {u} (Compound) binds {v} (Gene) DRD3
Metoclopramide {u} (Compound) palliates {v} (Disease) migraine
Metoclopramide {u} (Compound) is included by {v} (Pharmacologic Class) Dopamine D2 Antagonists
Metoclopramide {u} (Compound) causes {v} (Side Effect) Somnolence
Metoclopramide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Dopamine
Metoclopramide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Desvenlafaxine
Metoclopramide {u} may lead to a major life threatening interaction when taken with {v} Paliperidone
Metoclopramide (Compound) resembles Cinchocaine (Compound)
Metoclopramide (Compound) resembles Procaine (Compound)
Metoclopramide may cause a moderate interaction that could exacerbate diseases when taken with Procainamide
Metoclopramide (Compound) binds DRD3 (Gene)
Metoclopramide (Compound) palliates migraine (Disease)
Metoclopramide (Compound) is included by Dopamine D2 Antagonists (Pharmacologic Class)
Metoclopramide (Compound) causes Somnolence (Side Effect)
Metoclopramide may cause a minor interaction that can limit clinical effects when taken with Dopamine
Metoclopramide may cause a moderate interaction that could exacerbate diseases when taken with Desvenlafaxine
Metoclopramide may lead to a major life threatening interaction when taken with Paliperidone